Research Funded To Date
The Ben and Catherine Ivy Foundation is dedicated to finding a cure for brain cancer. We strive in improve the quality of life and increase the life expectancy of those diagnosed with brain cancer by funding promising research that creates more diagnostics and treatments for patients.
Since 2008, we have funded 33 separate institutions with over 107 different research grants totaling over $150 million. These grants have involved research in phase 0 clinical trials, biomarkers, genomics, imaging, immunotherapy, stem cell, vaccines, and the development of possible new drugs.
2023
NEUROLOGICAL SCIENCES INTERNSHIP PROGRAM AT TGEN DESIGNED TO GIVE HIGH SCHOOL AND UNDERGRADUATE STUDENTS INTENSIVE, HANDS-ON RESEARCH EXPERIENCE WORKING ALONGSIDE A MENTOR-SCIENTIST TO LEARN ABOUT TRANSLATIONAL RESEARCH WHILE INVESTIGATING QUESTIONS WITHIN THE NEUROLOGICAL SCIENCES.
PI: Kristen Kaus
Manager of Education and Outreach
Translational Genomics Research Institute (TGEN)
DEVELOP QUANTITATIVE METHODS TO ASSESS METHIONNINE METABOLISM AND TEST THE EFFICACY OF METHIONNE-DIRECTED THERAPEUTICS IN MOUSE MODELS AND PATIENTS WITH GLIOBLASTOMA
PIs: Daniel Wahl, MD, Ph.D.
Assistant Professor, Department of Radiation Oncology
University of Michigan
Costas Andreas Lyssiotis, Ph.D.
Associate Professor of Molecular and Integrative Physiology
University of Michigan
Wajd Al-Holou
Assistant Professor of Neurosurgery
University of Michigan
Deepak Nagrath
Assistant Professor of Biomedical Engineering
University of Michigan
PHASE I CLINICAL TRIAL TO EVALUATE THE FEASIBILITY, SAFETY, AND CLINICAL EFFICACY OF TGFβ-RESISTANT ILIRα2-CAR T CELLS FOR TREATMENT OF RECURRENT GLIOBLASTOMA
PIs: Christine Brown, Ph.D.
Professor, Department of Hematology and Hematopoietic Cell Transplantation and Immuno-Oncology
City of Hope
Darya Alizadeh, Ph.D.
Assistant Research Professor, Department of Hematology and Hematopoietic Cell Transplantation and Immuno-Oncology
City of Hope
DETERMINE THE STRUCTURAL BASIS AND MOLECULAR MECHANISM OF ACTION OF SUM01 DEGRADERS IN TREATMENT OF GLIOBLASTOMA, ALONE AND IN COMBINATION WITH CURRENT STANDARD CHEMO AND RADIOTHERAPY
PIs: Chunhai Charlie, MD, Ph.D.
Professor of Pathology and Laboratory Medicine
Indiana University
Yuichiro Takagi, Ph.D.
Associate Professor of Biochemistry and Molecular Biology
Indiana University
Marc S. Mendonca, Ph.D.
Professor Radiation Oncology
Indiana University
Anita C. Bellail, Ph.D.
Assistant Professor Pathology and Lab Medicine
Indiana University
Chafiq Hamdouchi, Ph.D.
Co-Director Cancer Drug Discovery and Development
Indiana University
Thomas M. O’Connell, Ph.D.
Associate Professor Otolaryngology-Head and Neck Surgery
Indiana University
ENGINEERING A MULTI-ANTIGEN TARGETING CAR T THERAPY WITH CONFINED ACTIVITES WITHIN THE TUMOR MICROENVIRONMENT TO TREAT ANTIGENICALLY HETEROGENOUS ADULT GLIOBLASTOMA.
PI: Leyuan Ma, Ph.D.
Assistant Professor Pathology and Laboratory Medicine
University of Pennsylvania, Children’s Hospital of Philadelphia
DEVELOP SMALL MOLECULE INHIBITORS OF A NEWLY IDENTIFIED ONCOGENE IN GLIOBLASTOMA
PIs: Hui Li, Ph.D.
Professor Pathology and Biochemistry and Molecular Genetics
University of Virginia
Michael Hilinski, Ph.D.
Professor Chemistry and Chemical Engineering
University of Virginia
DEVELOP AND TEST NEW THERAPIES FOR GLIOBLASTOMA USING MICORNAS
PIs: Roger Abounader, MD, Ph.D.
Professor of Microbiology, Immunology and Cancer Biology, Associate Director for Basic Research
University of Virginia
Jamie F. Mata, Ph.D.
Professor of Radiology and Medical Imaging, Assistant Director Center of In-vivo HPG MRI
University of Virginia
DEVELOP AND DEPLOY STRATEGIES FOR LEVERAGING MRI-GUIDED FOCUSED ULTRASOUND THERAPY TO POTENTIATE CAR-T CELL THERAPY AGAINST ADULT HIGH-GRADE GLIOMAS
PIs: Natasha D. Sheybani, Ph.D.
Assistant Professor and Research Director, UVA Focused Ultrasound Cancer Immunotherapy Center
University of Virginia
Dalia Haydar, Ph.D.
Research Faculty and Assistant Professor of Pediatrics
George Washington University